Pharmacokinetic and Pharmacodynamic Modeling for the Effect of Sodium–Glucose Cotransporter Inhibitors on Blood Glucose Level and Renal Glucose Excretion in db/db Mice-Reference-Cited by-同舟云学术

Pharmacokinetic and Pharmacodynamic Modeling for the Effect of Sodium–Glucose Cotransporter Inhibitors on Blood Glucose Level and Renal Glucose Excretion in db/db Mice

Published:2012-11 Issue:11 Volume:101 Page:4347-4356
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Yamaguchi Koji,Kato Motohiro,Ozawa Kazuharu,Kawai Takahiro,Yata Tatsuo,Aso Yoshinori,Ishigai Masaki,Ikeda Sachiya

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference31 articles.

1. Role of sodium–glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes;Abdul-Ghani;Endocr Rev,2011

2. Sodium–glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: A review of phase II and III trials;Kipnes;Clin Invest,2011

3. Renal Na+–glucose cotransporters;Wright;Am J Physiol Renal Physiol,2001

4. Molecular physiology of sodium–glucose cotransporters;Hediger;Physiol Rev,1994

5. Localization of the Na+–d-glucose cotransporter SGLT1 in the blood-brain barrier;Elfeber;Hitochem Cell Biol,2004

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption;ACS Omega;2022-12-15

2. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors;Diabetes, Obesity and Metabolism;2019-09-09

3. Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction;Cardiovascular Diabetology;2018-07-07

4. Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2016-09-08

5. A Pharmacokinetic/Pharmacodynamic Drug–Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs;Drug Research;2015-07-09